Introduction

Hereditary breast and ovarian cancer (HBOC) is caused by germline mutations in the BRCA1
and BRCA2 genes which are autosomal dominant tumor suppressor genes that help ensure DNA damage in the cell is repaired prior to cell replication. Since the discovery of the BRCA1 and BRCA2
genes in 1994 and 1995, respectively, considerable research has been completed to analyze the cancer risks associated with these genes (Miki et al., 1994; Wooster et al., 1995) . Individuals with a BRCA1 or BRCA2 mutation have up to an 84% lifetime risk to develop breast cancer and up to a 27% or 45% lifetime risk to develop ovarian cancer, respectively (Ford et al., 1998) . However, lifetime risks for cancers other than breast and ovarian cancer remain debated.
The National Comprehensive Cancer Network (NCCN) has compiled well-established screening and surveillance guidelines for BRCA mutation carriers. Recommendations to reduce risks for breast cancer in women include clinical breast exams beginning at age 25, annual breast MRI, or mammogram if MRI is unavailable, beginning at 25-29 years of age or based on family history, annual mammogram and breast MRI for women ages 30-75, and discussion of riskreducing mastectomies (NCCN, 2015) . Recommendations for women over age 75 should be considered on an individual basis (NCCN, 2015) . For ovarian cancer risk-reduction, recommendations should be given for a bilateral salpingo-oophorectomy between ages 35 and 40 and upon completion of child bearing (NCCN, 2015) . The NCCN recommends male BRCA carriers complete breast self-exams and clinical breast exams every 12 months beginning at age 35 (NCCN, 2015) . The guidelines also advise male BRCA2 carriers to begin, and BRCA1 carriers to consider, prostate cancer screening at age 40 (NCCN, 2015) . No specific guidelines exist for pancreatic cancer and melanoma which have an established association with BRCA mutations.
Prior studies investigating cancer risks other than breast and ovarian in BRCA1 and BRCA2 mutation carriers have reported inconsistent results and have been largely gathered from small, familial studies. One of the larger studies to date completed by The Breast Cancer Linkage Consortium (BCLC) in 1999 found BRCA2 mutation carriers have an increased risk for prostate and pancreatic cancer and a statistically significant increased risk for buccal cavity, pharynx, stomach, melanoma of the skin, gallbladder, and bile duct cancers (BCLC, 1999) . The increased risk for prostate and pancreatic cancer has been replicated by numerous other studies and the association between BRCA2 mutations and these cancers is accepted in clinical practice (BCLC, 1999; Iqbal et al., 2012; Johannsson et al., 1999; Lorenzo Bermejo & Hemminki, 2004; Mersch et al., 2014; Moran et al., 2012; van Asperen et al., 2005) .
Other studies describing increased risks for cancers other than breast and ovarian are conflicting. Numerous reports debate whether an increased lifetime risk for any cancer beyond breast and ovarian cancer even exists across both sexes and genes (Moran et al., 2012; Thompson & Easton, 2002) . Multiple studies have agreed upon a significantly increased risk for pancreatic, prostate, and stomach cancers in all BRCA mutation carriers, but a consensus of the lifetime risks for these cancers continues to be debated and researched (BCLC, 1999; Brose, 2002; Johannsson et al., 1999; Noh et al., 2012 ). An increased risk for colon cancer in BRCA mutation carriers has been described citing relative risks ranging from 0.82-4.8 in mutation carriers Sopik, Phelan, Cybulski, & Narod, 2014) . In 2014, Mersch, et al. completed one of the largest single institution studies of the incidence of non-breast and ovarian cancers in over 1,000 BRCA mutation carriers (Mersch et al., 2014 ). An increased incidence of pancreatic and prostate cancer in BRCA2 mutation carriers as well as increased occurrence of melanoma in BRCA1 carriers and cervical cancer in BRCA2 carriers was observed (Mersch et al., 2014) . Various other studies have reported an increased risk for melanoma of the skin, cervix, gallbladder, stomach, and uterine cancers; however, these have ranged from 1-to 4-fold increases, vary between BRCA1 and BRCA2 mutations, and are inconsistently reported (BCLC, 1999; Johannsson et al., 1999; Moran et al., 2012; Thompson & Easton, 2002; van Asperen et al., 2005) .
ovarian cancers, and this study aims to further clarify and characterize the spectrum of cancer risks evident in families with a known BRCA1 or BRCA2 mutation. It is essential to more clearly define the lifetime risks for non-breast and ovarian cancers associated with HBOC as they may inform the development of more comprehensive surveillance guidelines and improve the accuracy of risk assessment. This study sought to determine whether the incidence of cancers was higher in families with a BRCA mutation than the general population. We evaluated first degree relatives (FDR) and second degree relatives (SDR) of BRCA mutation carriers to describe the incidence of cancers in families with a BRCA mutation. To our knowledge this is the largest study to be completed on a cohort of families with a BRCA mutation. A retrospective chart review of the pedigrees previously collected during genetic counseling visits with confirmed deleterious BRCA1 or BRCA2 mutations were completed for this study.
Methods
This
Parental origin of the mutation was determined by the presence of a breast and/or ovarian cancer in a female first or second degree relative diagnosed before age 60 or a male first or second degree relative diagnosed with breast cancer at any age. Pedigrees that did not meet these criteria or had breast and/or ovarian cancers in both paternal and maternal family histories were reviewed by 3 authors (JP, JL, DN). If a consensus of the parental origin of the mutation could not be determined, the pedigree was excluded from the study. All FDR and SDR of the proband on the affected parental side were included in this analysis. Relatives with no reported age or no reported age of cancer diagnosis were excluded in order to accurately account for an individual's contribution of cancer risk to the study population which was calculated according to 5 year age intervals.
The incidence of cancers found in the study population was compared to the general 
Results
We identified 1,086 individuals with a deleterious BRCA1 or BRCA2 mutation from 1997-2014. In 164 of the pedigrees, the parental origin of the mutation could not be determined and were excluded. Sixty-one other pedigrees were eliminated from the study for numerous reasons:
15 of the known mutation carriers did not have a pedigree available; 41 pedigrees lacked a comprehensive family history and did not include three generations; 2 pedigrees had the presence of another genetic conditions in the family (hereditary retinoblastoma and neurofibromatosis type 1); and 3 pedigrees had both a BRCA1 and BRCA2 mutation in the family. Seventy-seven of the reviewed pedigrees were determined to be duplicates due to another individual in the same family seeking site-specific testing. In these cases, the proband of a given pedigree was considered to be the individual who presented to clinic first and only the most recent version of a family's pedigree in the database was included in the analysis. In total, 784 unique pedigrees were analyzed ( Figure   1 ). Table 1 . The age of the study population followed a normal distribution curve with an average age of 45.2 years old and a range of 1-104 years old. Majority of the population was living at the time the pedigree was collected (6,545, 72%). Male breast cancer, which has a well-described association with BRCA mutations, was not analyzed as it was not included in the USCS report due to its low prevalence in the general population. However, 24 cases of male breast cancer were identified in the study population; 12
were of BRCA1 families and 12 were of BRCA2 families. The average age of diagnosis of male breast cancer in BRCA1 families was 48 years (27-75 years) and 64 years (47-75 years) in BRCA2 families.
We found multiple increased and decreased SIRs among BRCA1 and BRCA2 families described in Tables 2 and 3 . We observed an increased SIR in BRCA1 families for breast cancer (SIR In BRCA2 families a decreased SIR for kidney, lung, Non-Hodgkin's lymphoma, thyroid, and uterine cancer was observed. Men in the BRCA1 population had a decreased SIR for kidney, lung, NonHodgkin's lymphoma, oral cavity, and prostate cancer and men in BRCA2 families had a decreased SIR for Non-Hodgkin's lymphoma. Women of BRCA1 families had a decreased SIR for lung, NonHodgkin's lymphoma, and thyroid cancer while women of BRCA2 families had a decreased SIR for lung, melanoma, thyroid, and uterine cancer. 
Discussion
This study aimed to further define the cancers associated with BRCA mutations through analysis of the incidence of cancers in first and second degree relatives of known BRCA1 and BRCA2 mutation carriers. The results confirm the recognized increased incidence of breast and ovarian cancer in females with a BRCA mutation. Additionally, this study confirms an association between BRCA mutations and pancreatic cancer based on the increased incidence of pancreatic cancer in BRCA2 families and the trending increased incidence of pancreatic cancer in BRCA1 families. The increased SIRs for breast and ovarian cancer in both BRCA1 and BRCA2 families and for pancreatic cancer in BRCA2 families are consistent with results from Mersch, et al. who examined the incidence of non-breast and ovarian cancers in the BRCA mutation-positive probands of this current study (Mersch et al., 2014) . The increased incidence of prostate cancer in BRCA2 mutation carriers found by Mersch, et al. is also supported by this study when analyzing only FDR in the study population.
Several studies have investigated the cancer risks for HBOC in cohorts of individuals without confirmed BRCA1 or BRCA2 mutations similar to this study population. In studies regarding BRCA1, increased risks for pancreatic, prostate, and uterine body/cervical cancer have been reported in cohorts of individuals with unknown BRCA mutation carrier status (Thompson & Easton, 2002) . Our results are consistent with the increased incidence of pancreatic cancer, but failed to find an association with prostate cancer or uterine body/cervical cancer. In BRCA2 research, increased risks for breast, ovarian, pancreatic, prostate, bone, and pharynx cancer, and uveal melanoma have been reported in populations which include unconfirmed BRCA mutation carriers (Moran et al., 2012; van Asperen et al., 2005) . Melanoma, breast, ovarian, pancreatic, and prostate cancers are all mentioned in the NCCN guidelines for HBOC (NCCN, 2015) . Excluding melanoma, these findings were replicated when considering just FDR. The increased risks for bone and pharynx cancer identified by Van Asperan, et al. have not been replicated to our knowledge (van Asperen et al., 2005) . This study did not analyze bone cancer and found no significant incidence of pharynx cancer.
No previously unreported associations of specific cancers with BRCA mutations were identified in this study and relatively few cancers had a significantly increased SIR when compared to other reports. However, many of these studies were based on analysis of confirmed BRCA1 and BRCA2 mutation carriers (Brose, 2002; Iqbal et al., 2012; Johannsson et al., 1999; Mersch et al., 2014; Noh et al., 2012; Phelan et al., 2014) . Because only half of our study population is assumed to have a BRCA mutation, we expected that cancers associated with BRCA mutations would not have as high an incidence as they would in a population comprised solely of known mutation carriers. Still, the outcomes of the present study may be more helpful in the development and review of screening protocols for HBOC because individuals seeking surveillance may be at risk for a known familial mutation but be untested.
Focusing on only FDR in the study population is beneficial to account for patient-reported family histories and should provide the most precise and accurate interpretation of results. This study relies on the accuracy of reported family histories which has been shown to be reduced in distant relatives. Studies examining the accuracy of patient-reported family histories indicate that the site of a cancer diagnosis in FDR and SDR is correctly reported in 78-95% and 53-67% of cases, respectively (Love, Evans, & Josten, 1985; Schneider et al., 2004; Ziogas & Anton-Culver, 2003) .
When considering only FDR, the incidences of cancers in the study population align almost completely with the previously established cancer associations for BRCA mutations. FDR of BRCA1 mutation carriers demonstrated an increased SIR for breast, ovarian, and pancreatic cancer and the FDR of BRCA2 carriers likewise revealed an increased SIR for breast, ovarian, and pancreatic cancer in addition to a trending increased SIR for prostate cancer. These cancer associations are all reported by the NCCN and information regarding risk reduction and surveillance recommendations for these cancers are addressed in the guidelines for HBOC (NCCN, 2015) . Furthermore, no decreased SIRs were observed in the population of only FDR.
Studies suggest that underreporting of cancer is more common than over reporting of cancers in family histories (Love et al., 1985; Ozanne et al., 2012; Quillin et al., 2006; Ziogas & Anton-Culver, 2003) . The overall accuracy of patient-reported family history is dependent on age, education, sex, degree of relation, and socioeconomic status of the patient or historian (Ozanne et al., 2012; Quillin et al., 2006; Schneider et al., 2004) . Family structure and dynamics, social stigma, and communication barriers may likewise contribute to an underreporting bias in a family history.
Also, for individuals of older generations, cancers may have gone undiagnosed as cancer detection and prevention measures improve with time and new technology (Singh, Sethi, Raber, & Petersen, 2007) . Moreover, pedigrees in which a complete family history was not reported (i.e. no paternal history known) were eliminated from the study if the parental origin of the mutation was not confirmed or could not be inferred. The influence of these factors may be reduced in the FDR population and may also provide explanations for the number of decreased SIRs observed in the overall study population when SDR were included in the analysis.
The average age of diagnosis of breast and ovarian cancer in individuals with BRCA mutations is expected to be lower than an individual without a mutation in the general population (Litton et al., 2012; Panchal et al., 2010) . The average age of diagnosis for breast and ovarian cancer in the general population is 61 years old and 63 years old, respectively (Howlader N, 2014) .
The average age of breast cancer diagnosis in the study population was 47.8 years old and 54.4 years old for ovarian cancer. This data generally agrees with recommendations of the NCCN to begin breast imaging in mutation carriers at 25 years of age as only 6 of the 968 (0.62%) reported cases of breast cancer were diagnosed prior to age 25. The NCCN guidelines do account for the use of family history information for making individualized screening recommendations (NCCN, 2015) .
Therefore some of these individuals may have begun screening before age 25 based on family history. The NCCN also recommends prophylactic bilateral salpingo-oophorectomy at 35-40 years and upon completion of child-bearing (NCCN, 2015) . Fourteen of the 166 (8.4%) cases of ovarian cancer were diagnosed prior to age 35 and 28 (16.9%) cases were diagnosed prior to age 40. Again, the NCCN guidelines advise that clinicians consider personal and family history information when making recommendations.
While this study allowed for analysis of a large number of relatives, the data is limited to one time point, as this was a retrospective data collection, so instances of cancer diagnosed after the date the pedigree was last updated are not included. For example, when interpreting the current results for prostate cancer, previous literature and the NCCN report an increased risk for prostate cancer in male BRCA2 mutation carriers and a likely increased risk in BRCA1 mutation carriers.
Therefore we expect an increased SIR for prostate cancer in the study population. However, the results of this study found a decreased SIR for BRCA1 mutation families. The average age of men in the BRCA1 population was 43.8 years old (1-104 years) and the average age of prostate cancer diagnosis is 66 years old in the general population with BRCA carriers under age 65 having an increased relative risk for prostate cancer of 1. 44-3.75 (Howlader N, 2014; Leongamornlert et al., 2012; Thompson & Easton, 2002) . Therefore, more of the men in the BRCA1 study cohort may develop prostate cancer in their lifetime which would increase the incidence in the study population and alter results.
Given that family history of cancer can evolve over time, the statistical analysis did account for each individual's contribution to the cancer risk of the study population based on ethnicity, sex, and age in 5-year intervals. Similarly, the pedigrees in the analysis were prospectively updated if on the pedigree, then that individual would have been excluded from this study consequently decreasing the incidence of that cancer in the study population. Therefore, cancers without a previous association to HBOC or a hereditary cancer syndrome may be underreported in the study population. Finally, the data cannot be generalized to individuals of all ethnicities given that the study population is predominantly Caucasian.
Moving forward, studies may wish to focus on non-Caucasian ethnicity specific cancer risks in HBOC because to our knowledge, most other studies on BRCA mutation carriers are based on a majority Caucasian population. Further investigation to obtain more specific lifetime relative risks for the cancers associated with HBOC should also be completed. Cohorts of known BRCA mutation carriers with their at-risk family members can be used as an unbiased population to better determine these risks and define age-specific incidence rates for more appropriate risk assessments for BRCA families. Additionally, more work to enhance screening and surveillance guidelines for mutation carriers is indicated as pancreatic cancer currently does not have wellestablished surveillance methods and recommendations for prostate cancer screenings are vague.
Screening guidelines from the NCCN acknowledge all of the cancer associations of BRCA mutations identified in this study, but risk reduction data and strategies may still be evolving.
Conclusion
The utilization of a cohort of individuals with an unknown BRCA mutation status from families with a known BRCA mutation allowed for a large sample size that demonstrated a 
